SHINGRIX INFORMATION & IMPLEMENTATION
A GUIDE FOR NURSES & OFFICE STAFF

SHINGRIX
(ZOSTER VACCINE RECOMBINANT, ADJUVANTED)

**Indication**
SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Please see Important Safety Information throughout and click here for full Prescribing Information for SHINGRIX, also available at SHINGRIXHCP.com.
He’s pretty healthy, but he’s over 50 years of age. No matter how much he exercises or how good his diet is, he’s still at risk for shingles.

99% of people 50 years of age and older are infected with VZV. In 1 out of 3 people, the dormant virus reactivates and causes shingles.

A dominant driver of shingles is age-related decline in immunity, or ARDI.

- Increasing age causes a natural decline in immunity
- As immune function declines, there is a reduction in the number and functionality of immune cells that prevent reactivation of VZV
- ARDI leads to a sharp increase in the incidence and severity of shingles

Important Safety Information
- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX

Please see Important Safety Information throughout and click here for full Prescribing Information for SHINGRIX, also available at SHINGRIXHCP.com.
HELPING YOUR DOCTOR PROTECT PATIENTS AGAINST SHINGLES

- Review medical records to identify appropriate patients
- Inform patients that they may be eligible to receive SHINGRIX
- Provide patient-friendly handout information about SHINGRIX
- Confirm insurance coverage for patient

“After reviewing your chart, I noticed that you may be eligible for the shingles vaccine. Don’t hesitate to ask your doctor if you’d like more information or if you have any questions regarding the vaccine.”

Important Safety Information (cont’d)
- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX

Please see Important Safety Information throughout and click here for full Prescribing Information for SHINGRIX, also available at SHINGRIXHCP.com.
INFORMING PATIENTS OF POSSIBLE ADVERSE EVENTS

Patients will want to know what kind of side effects they may experience with SHINGRIX. Let them know that:

“Side effects can include pain, redness, and swelling at the injection site. You may also experience muscle pain, fatigue, headache, shivering, fever, or upset stomach.”

“The local and general adverse reactions seen with SHINGRIX had a median duration of 2 to 3 days.”

Important Safety Information (cont’d)

- In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX.
- Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope.

Please see Important Safety Information throughout and click here for full Prescribing Information for SHINGRIX, also available at SHINGRIXHCP.com.
REMINDING PATIENTS TO RETURN FOR THEIR SECOND DOSE

SHINGRIX is given as a 2-dose series. The second dose should be given 2 to 6 months after the first dose is received. Remind patients that the second dose of SHINGRIX is not a nice-to-have, it’s an important-to-have—and you want to ensure they receive theirs.10

Encourage your patients to sign up for second dose reminders at SHINGRIXreminder.com

Find more helpful resources for your patients at SHINGRIXHCP.com

Important Safety Information (cont’d)
• Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
• Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)

Please see Important Safety Information throughout and click here for full Prescribing Information for SHINGRIX, also available at SHINGRIXHCP.com.
SHINGRIX is $0 for almost everyone 50 years and older.¹¹-¹³

95% of commercial patients pay $0 for SHINGRIX, with average copays of just $4 or less.¹¹,¹²,†

All Medicare Part D patients can receive SHINGRIX for $0 at their pharmacy.¹¹,¹³

“My doctor recommended SHINGRIX. Is it covered by my health insurance?”

“My doctor mentioned I could get SHINGRIX at a pharmacy?”

“Most adults 50 years and older are covered for SHINGRIX. If you have private insurance, you’ll typically pay no out-of-pocket cost per dose. If you’re covered under Medicare Part D, you can receive SHINGRIX for $0 at the pharmacy.”¹¹,¹³

“As with flu vaccines, you can get SHINGRIX at a pharmacy. If any of your in-network pharmacies don’t carry it, you can also visit scheduleSHINGRIX.com. Let us know when you have received either of the doses.”

Important Safety Information (cont’d)
- The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women

Please see Important Safety Information throughout and click here for full Prescribing Information for SHINGRIX, also available at SHINGRIXHCP.com.

*Coverage and cost may vary and are subject to change without notice. Reimbursement decisions are made by individual insurance plans.

†SOURCE: Managed Markets Insight & Technology, LLC, Database as of October 2022. Coverage represents access to reimbursement from a health plan with restrictions appropriate to the Advisory Committee on Immunization Practices (ACIP) recommendation(s) and/or prescribing information. Veterans Affairs (VA) and Indian Health Service (IHS) lives have been omitted when calculating the percentage of lives.
Getting SHINGRIX for your office is simple when ordering through either your preferred wholesale distributor or GSKdirect.com.

GSK has removed SHINGRIX ordering caps and is currently meeting demand across all distribution channels. You are encouraged to order through whichever channel you prefer to help meet your SHINGRIX needs.

Please see Important Safety Information throughout and click here for full Prescribing Information for SHINGRIX, also available at SHINGRIXHCP.com.
Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
- In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
- Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope

Important Safety Information (cont’d)

- Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
- Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)
- The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
- It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Please see Important Safety Information throughout and click here for full Prescribing Information for SHINGRIX, also available at SHINGRIXHCP.com.
REFERENCES